Although a few of the potential treatments have been authorized for emergency/compassionate use, none of the drugs have been approved for widespread .. Read more clinical use in the US. The challenge with the SARS-CoV-2 is that it not only affects the respiration system, but also attacks the cardiovascular, nervous, digestive and other major systems of the body. Companies, from large biopharm to smaller biotechs and laboratories, are looking at the various impacts of the disease, as well as developing treatments to help reduce the multitude and severity of symptoms, from impact of cytokine storm, to ARDS, to severe inflammation and bacterial infections. CHIs Therapeutic Interventions for COVID-19 conference invites scientists from pharma, biotechs and academia, who are driving innovation in the SARS-CoV-2 treatment to share their insights, knowledge gleaned, and analysis of data from clinical trials to help speed therapeutic development.
- Share your Experience